Epithelial-immune interface in asthma: Mechanistic insights driving novel therapeutic strategies
Seminars in Immunopathology · 31.07.2026 · 48 (1)
DOI: 10.1007/s00281-026-01079-8 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Seminars in Immunopathology, online erschienen am 31.07.2026. Verfasst von Jingyi Deng und 7 weiteren Autor:innen. Beteiligte Einrichtung: Dongguan Key Laboratory of Immune Regulation and Prevention of Pulmonary Diseases, Liaobu Hospital of Dongguan City, Dongguan, 523430, China. Hauptthemen laut MEDLINE: Asthma, Epithelial Cells, Respiratory Mucosa. Die Arbeit nennt 158 Literaturangaben.
Abstract (Originalsprache)
Asthma is a heterogeneous chronic respiratory syndrome driven by complex interactions between environmental triggers and the host immune system while biologic therapies targeting downstream type 2 cytokines (e.g., anti-IL-5, anti-IL-4Rα) have improved outcomes, the recent success of upstream epithelial-targeting agents like Tezepelumab highlights the potential of targeting disease at its source. Accordingly, recent conceptual advances have redefined the airway epithelium from a passive structural shield to an active immunometabolic hub. This review provides a concise synthesis of emerging mechanistic insights into how airway epithelial cells (AECs) orchestrate both innate and adaptive immune responses. We systematically map the bidirectional crosstalk between the epithelium and diverse immune populations, highlighting how metabolic reprogramming, vesicle-mediated intercellular communication, and neuro-immune circuitry act synergistically to sustain chronic airway inflammation. Furthermore, we explore how these dynamic networks dictate distinct asthma endotypes, ranging from classic type 2 to non-type 2 phenotypes. By delineating these underlying pathobiological mechanisms, this article underscores the translational potential of targeting upstream epithelial signaling. Ultimately, advancing our understanding of this epithelial-immune interface paves the way for emerging precision therapeutics aimed at modifying disease progression and restoring airway homeostasis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Dongguan Key Laboratory of Immune Regulation and Prevention of Pulmonary Diseases, Liaobu Hospital of Dongguan City, Dongguan, 523430, China.
- Guangdong Provincial Key Laboratory of Medical Immunology and Molecular Diagnostics, College of Medical Technology, Guangdong Medical University, Dongguan, 523808, China.
- Dongguan Key Laboratory of Immune Regulation and Prevention of Pulmonary Diseases, Liaobu Hospital of Dongguan City, Dongguan, 523430, China. 358581244@qq.com.
- Dongguan Key Laboratory of Immune Regulation and Prevention of Pulmonary Diseases, Liaobu Hospital of Dongguan City, Dongguan, 523430, China. ouyangsd@gdmu.edu.cn.
- Guangdong Provincial Key Laboratory of Medical Immunology and Molecular Diagnostics, College of Medical Technology, Guangdong Medical University, Dongguan, 523808, China. ouyangsd@gdmu.edu.cn.
Zitieren
APA
Deng, J., Zhao, J., Zhu, W., Li, Y., Nie, D., Zhong, Y., Lian, X., & Ouyang, S. (2026). Epithelial-immune interface in asthma: Mechanistic insights driving novel therapeutic strategies. Seminars in Immunopathology, 48(1). https://doi.org/10.1007/s00281-026-01079-8
Vancouver
Deng J, Zhao J, Zhu W, Li Y, Nie D, Zhong Y, et al. Epithelial-immune interface in asthma: Mechanistic insights driving novel therapeutic strategies. Seminars in Immunopathology. 2026;48(1). doi:10.1007/s00281-026-01079-8
BibTeX
@article{Deng2026,
author = {Deng, Jingyi and Zhao, Jun and Zhu, Wenlu and Li, Yuanhui and Nie, Dexin and Zhong, Yuyu and Lian, Xinlong and Ouyang, Suidong},
title = {Epithelial-immune interface in asthma: Mechanistic insights driving novel therapeutic strategies},
journal = {Seminars in Immunopathology},
year = {2026},
volume = {48},
number = {1},
doi = {10.1007/s00281-026-01079-8}
}
EUVIMED